DOCSLIB.ORG

Pregabalin Lercanidipine Hydrochloride Ulipristal Acetate

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pregabalin Lercanidipine Hydrochloride Ulipristal Acetate API Pregabalin Lercanidipine Hydrochloride Ulipristal Acetate Aprepitant/Aprepitant Perindopril Arginine Rasagiline mesylate Dapoxetine Perindopril tert-butylamine salt Brinzolamide Lurasidone Hydrochloride Troxagliptin succinate Teriflunomide Pazopanib Hydrochloride/Pazopanib Ranolazine Cinacalcet Hydrochloride Tetrabenazine Lifitegrast Deoxycholic acid Vardenafil Dimethyl fumarate Linagliptin Tavaborol Apremilast Idebenone Edoxaban Pabxilib Lapatinib ditosylate Tippyridine Hydrochloride Itraconazole hydrochloride Clofarabine Pleasant Adapalene Oseltamivir Phosphate Vinpocetine Celecoxib Bivalrudine Canagliflozin Paliperidone Ticagrelor Temozolomide Valganciclovir hydrochloride Salmeterol xinafoate Fondaparinux Letrozole Bosentan Solinasine Succinate Bemeprost Escitalopram oxalate Fulvestrant Gabapentin Saxagliptin hydrochloride Ebastine Dabigatran etexilate mesylate Mebeverine Nilotinib Calcipotriol Pallidone palmitate Voriconazole Paroxetine Hydrochloride Imatinib Metaxalone Abidol Lamotrigine Avanafil Fimasartan potassium Lacosamide Desogestrel Drospirenone Bouracetam Engligliflozin Enzalutamide Esomeprazole Sodium Bedaquinoline fumarate Rotigotine/Rotigotine Tomoxetine Chloride Lanthanum Carbonate Prasugrel Diacerein Mycophenolate Sodium Fluticasone furoate Lenalidomide Isodiazep Toremifene citrate Alfurazosin Emtricitabine Beraprost sodium Calcitriol Etonogestrel Bunanserin Sildenafil Citrate Epalrestat Rupatadine fumarate Fluvoxamine maleate Trifluridine Posaconazole Acatadine Tiotropium Bromide Nintedanib ethanesulfonate Glycopyrrolate Netupitant Atovar constant Darunavir Tacrolimus Olopatadine Hydrochloride Gefitinib Pramipexole chloride Baclofen Rosiglitazone maleate Tibolone Titagliptin Hydrobromide Bendamustine hydrochloride Brimonidine tartrate Duloxetine Hydrochloride Abiraterone Acetate Glucosamine sulfate sodium chloride double salt Sagrelate Hydrochloride Varenicline tartrate Cetrorelix Acetate Lornoxicam Esomeprazole Magnesium Anastrozole Mesalazine Eltropolamine Acotiamide Fingolimod Hydrochloride Bupivacaine base Diquafoxol Ertapenem Dantrolene sodium Etocoxib Dapagliflozin Fosapidem dimethyl meglumine Fesoterodine fumarate Creboro Cefditoren pivoxil Ertapenem Sodium Eplerenone Gestodene Shacubatril and Valsartan Sodium Davapyridine Cyclobenzaprine Tenofovir Propofol Fumarate Sleppug Bortezomib Sodium picosulfate Ezetimibe Travoprost Topiramate Entacapone Etofenamate Sitagliptin Phosphate Macitentan Micafungin Sodium Sevelamer Carbonate Oxcarbazepine Carprost tromethamine Ripivirin Latanoprost Naltrexone Hydrochloride Mesna Perampanel Ondansetron Levothyroxine Sodium Tolvaptan Icatibant acetate Ramelteon Topiroxostat Protein iron succinate Corvette Dutasteride Sirolimus Azilsartan Azilsartan medoxomil Betamethasone Dipropionate Clobetasol propionate Mirabegron sugammadex sodium Levosimendan Vothiaxetine hydrobromide Doxylamine succinate Levalbuterol Hydrochloride Vilazodone hydrochloride Delaros Pimovanserin tartrate Goserelin Rebamipide Idecalcidol Formoterol fumarate Linezolid Fluticasone propionate Goserelin acetate Tofacitib citrate Neostigmine methosulfate Sorafenib tosylate Erlotinib Hydrochloride Epistin Tafluprost Guanfacine Hydrochloride Pinaverium bromide Pirfenidone Amorolfine Hydrochloride Tamsulosin Hydrochloride Lopinavir Ritonavir Olapali Carfilzomib Pomalidomide Lenvatinib mesylate Nafamostat mesylate Suvorsen Ivabradine Hydrochloride Gadoteridol Dienogest Benidipine Hydrochloride Cabozantinib Malate Dofelite/Dofelite Desonide Compound digestive enzyme Azacitidine Homatropine hydrobromide Sunitinib malate Aluminum magnesium plus Ciclesonide Gadobutrol Sofosbuvir/Sofosbuvir Vilanterol triphenylacetate Efluconazole Ferric carboxymaltose Riluzole Torasemide Dexlansoprazole Cefcapene pivoxil Misoprostol-Hydroxypropyl Methyl Cellulose Oxybutynin Hydrochloride Roxastat Articaine Anhydrous sodium sulfate Leuprolide Acetate Dexzopiclone Teicoplanin Epipiprazole Ferric Citrate Epoprostol Sodium Eslicarbazepine acetate Metadoxine Febuxostat Fenofibrate Nalmefene Hydrochloride Silodosin Obeticholic Acid Epinephrine tartrate Dasatinib Carbidopa Ramipril Lauroyl aripiprazole Vigabatrin Amiodarone Hydrochloride Chlorpheniramine maleate Metronidazole Etomidate Bromhexine Hydrochloride Clopidogrel Bisulfate Triptorelin Aripiprazole Toppicamide Exemestane Chlorhexidine Gluconate Ipratropium bromide Meta-hydroxylamine bitartrate Tirofiban hydrochloride Amisulpride Acetazolamide Acetaminophen magnesium hydroxide Mosapride citrate Propofol Donepezil Hydrochloride Bisoprolol fumarate Palonosetron Hydrochloride Lamivudine Ursodeoxycholic acid Alendronate Aceclofenac Raloxifene Hydrochloride Benzbromarone Tramadol hydrochloride Famotidine Hydroxychloroquine Sulfate Oxaliplatin Metoprolol Succinate Pantoprazole Sodium Sodium bicarbonate Magnesium Trisilicate Aluminum hydroxide Azelaic Acid Levetiracetam Irinotecan Hydrochloride Dipyridamole Chlorpromazine Hydrochloride Rosuvastatin calcium Digoxin Desloratadine Mometasone furoate Brompistigmine Bumetanide Minocycline Hydrochloride Atropine Sulfate Glucosamine Hydrochloride Montelukast sodium Naphazoline Hydrochloride Capecitabine Imiquimod Budesonide Butenafine Hydrochloride Mesoparmo Benazepril Hydrochloride Tegafur Terbutaline Sulfate Bicalutamide Benzoyl peroxide Riociguat Apixaban Fluorescein Sodium;Fluorescein disodium Teriparatide Acetate Propranolol hydrochloride Etoposide Carvedilol Aluminum Phosphate Fluconazole Fexofenadine hydrochloride Nebivolol Hydrochloride Methylprednisolone acetate Tizanidine Cefprozil Cyclosporine Diphenhydramine hydrochloride Melphalan Iron oxyhydroxide Pimecrolimus Simethicone Carbon[13C]-urea Nafuraphine Sodium Divalproate Vitamin B6 Tadalafil Zinc gluconate Safinamide Mesylate Selenium Disulfide Levocabastine hydrochloride Vitamin D3 Doxofylline Mecobalamin Midostaurin Adenosine Tolterodine tartrate Bepotastine Bupivacaine Hydrochloride Fluoxef sodium Fluvastatin sodium Gemcitabine hydrochloride Famciclovir insulin Alprostadil Salbutamol Sulfate Cefazolin Sodium Methoxyphenamine hydrochloride Nystatin Ornidazole Irbesartan Cilostazol Sodium Valproate Atorvastatin calcium Minoxidil Pralidoxime Bisacodyl Ethylphenidate Ropivacaine hydrochloride Naloxone Hydrochloride Papaverine Hydrochloride Cefdinir Albendazole Glimepiride Diltiazem Sodium selenite Venlafaxine Hydrochloride Rabeprazole Sodium Levoleucovorin Zoledronic acid Memantine Hydrochloride Moxifloxacin Hydrochloride Risperidone Docetaxel Entecavir Cefpodoxime proxetil Benserazide Esomeprazole/Esomeprazole Favipiravir Orlistat Nifuratel Agomelatine Deferiprone Lisinopril Luliconazole Sulfamethoxazole Naproxen Corbistat Roxatidine Acetate Hydrochloride Desvenlafaxine succinate Eribulin mesylate Ambroxol hydrochloride Agatroban Metoclopramide hydrochloride Ulinastatin Vono Lazan Fumarate Efavirenz/Efavirenz Roxatidine Acetate Rivaroxaban Osimertinib mesylate Loperamide hydrochloride Adrenaline Bilastine Pabisstat Opemifene Dronedarone hydrochloride Ferrous sulfate Parecoxib sodium Procapride Lorapitant Gadolinium Diamine Right Rezoo Ziprasidone Mesylate Methylprednisolone Regofinil Azelastine Hydrochloride Acetyl methylprednisolone Levodopa Micuronium chloride Pukanatide Eperisone Hydrochloride Buspirone Olanzapine Afatinib maleate Diosmin Leflunomide Linaclotide Polymyxin E sodium methanesulfonate Piroxicam Zaleplon Peramivir Crotamiton/Universal L-Milnacipran Hydrochloride Bromfenac Sodium Ferrous Fumarate Reserpine Tedizolamide Phosphate Ilaprazole Iomeprol Avibactam Sodium Nizatidine Drotaverine Hydrochloride Sucralfate Trimetazidine hydrochloride Prilocaine Vitamin K2 (Tetraene Menadione) Ibrutinib Phenylephrine Hydrochloride Remdesivir Bromocriptine mesylate Calcium acetate Axitinib Racecadotril Bupropion Mitiglinide calcium Rifabutin Emestine Pentoxifylline Liothyronine Verapamil Minodronic acid Aminolevulinic acid hydrochloride Rivastigmine bitartrate Tiapride Pitavastatin calcium Methimazole Dulutvir Sodium/ Dolutegravir Sodium Naproxen Sodium Nitazoxanide Isoproterenol hydrochloride Pilocarpine hydrochloride Hydroxyurea Cytarabine Adefovir dipivoxil Chlorzoxazone Fluorometholone Polysaccharide iron complex Betahistine Mesylate Nicardipine Hydrochloride Topotecan Hydrochloride Norethindrone Progesterone Benzoyl Metronidazole Flurbiprofen sodium Dinoprostone Capsaicin Dolutegravir Sodium Alvatropol maleate Defkot Lenatinib maleate/neratinib maleate Everolimus Trazodone hydrochloride Dorzolamide hydrochloride Hydroxycobalamin Hydrochloride Estradiol Iron sucrose Doxazosin mesylate Milnacipran Hydrochloride Tazarotene Fenoterol Chymotrypsin Aclidinium bromide Gemfibrozzi Corticotropin Levocetirizine Hydrochloride Indapamide Alfacalcidol Lactulose solution Lysozyme Cetylpyridinium chloride Halobetasol Propionate Tasmetron Zidovudine Foscarnet Sodium Decitabine Vidagliptin Pancuronium bromide Nitroglycerin Triamcinolone Acetate Levonorgestrel Esmolol hydrochloride Cefoxitin Sodium Estriol Ozefloxacin Cefmetazole Sodium Fosfomycin tromethamine Sodium Nitroprusside Meloxicam Bepradoic acid Dapsone Azathioprine Cabazitaxel Fenofibrate choline Rizatriptan benzoate Droxidopa CAS 148553-50-8 132866-11-6 126784-99-4 170729-80-3 612548-45-5 161735-79-1 119356-77-3 107133-36-8 138890-62-7 367514-88-3 1029877-94-8 108605-62-5 635702-64-6 95635-55-5 364782-34-3 58-46-8 1025967-78-5 83-44-3 224785-90-4 624-49-7 668270-12-0 174671-46-6 608141-41-9 58186-27-9 912273-65-5 571190-30-2 388082-78-8 183204-72-0 84625-61-6 123318-82-1 110078-46-1 106685-40-9 204255-11-8 42971-09-5
Load more

Recommended publications
  • List of New Drugs Approved in India from 1991 to 2000
    LIST OF NEW DRUGS APPROVED IN INDIA FROM 1991 TO 2000 S. No Name of Drug Pharmacological action/ Date of Indication Approval 1 Ciprofloxacin 0.3% w/v Eye Indicated in the treatment of February-1991 Drops/Eye Ointment/Ear Drop external ocular infection of the eye. 2 Diclofenac Sodium 1gm Gel March-1991 3 i)Cefaclor Monohydrate Antibiotic- In respiratory April-1991 250mg/500mg Capsule. infections, ENT infection, UT ii)Cefaclor Monohydrate infections, Skin and skin 125mg/5ml & 250mg/5ml structure infections. Suspension. iii)Cefaclor Monohydrate 100mg/ml Drops. iv)Cefaclor 187mg/5ml Suspension (For paediatric use). 4 Sheep Pox Vaccine (For April-1991 Veterinary) 5 Omeprazole 10mg/20mg Short term treatment of April-1991 Enteric Coated Granules duodenal ulcer, gastric ulcer, Capsule reflux oesophagitis, management of Zollinger- Ellison syndrome. 6 i)Nefopam Hydrochloride Non narcotic analgesic- Acute April-1991 30mg Tablet. and chronic pain, including ii)Nefopam Hydrochloride post-operative pain, dental 20mg/ml Injection. pain, musculo-skeletal pain, acute traumatic pain and cancer pain. 7 Buparvaquone 5% w/v Indicated in the treatment of April-1991 Solution for Injection (For bovine theileriosis. Veterinary) 8 i)Kitotifen Fumerate 1mg Anti asthmatic drug- Indicated May-1991 Tablet in prophylactic treatment of ii)Kitotifen Fumerate Syrup bronchial asthma, symptomatic iii)Ketotifen Fumerate Nasal improvement of allergic Drops conditions including rhinitis and conjunctivitis. 9 i)Pefloxacin Mesylate Antibacterial- In the treatment May-1991 Dihydrate 400mg Film Coated of severe infection in adults Tablet caused by sensitive ii)Pefloxacin Mesylate microorganism (gram -ve Dihydrate 400mg/5ml Injection pathogens and staphylococci). iii)Pefloxacin Mesylate Dihydrate 400mg I.V Bottles of 100ml/200ml 10 Ofloxacin 100mg/50ml & Indicated in RTI, UTI, May-1991 200mg/100ml vial Infusion gynaecological infection, skin/soft lesion infection.
    [Show full text]
  • Download Product Catalog
    Total Quality Medications Product Portfolio Rx Product name Dosage form Generic name Pack size Indications A- Alimentary tract and metabolism A02B – Proton pump inhibitor Omecarbex 20 mg H.G Cap Omeprazole +Na 20 Caps Acid reflux and Ulcers Omecarbex 40 mg H.G Cap Carbonate 20 Caps Acid reflux and Ulcers A06A - Laxatives Amiprostone 8 mcg S.G Cap Lubiprostone 20 Capsules Laxative Amiprostone 24 mcg S.G Cap Lubiprostone 10 Capsules Laxative A07A- Intestinal Anti-infective Anti-diarrheal Gastrobiotic 200 mg Tablets Rifiximin 20 Tablets Antidiarrheal Gastrobiotic 550 mg Tablets Rifiximin 30 Tablets Antidiarrheal Nitazode 100 mg/5 ml Suspension Nitazoxanide Bottle 60 ml Antiprotozoal A10B- Oral Anti -diabetics A10-BD - Oral hypoglycemic associations Glimepiride+ Improve glycemic control for type 2 Glimepiride plus 4/30 Tablets 30 Tablets Pioglitazone Hcl diabetes Glimepiride+ Improve glycemic control for type 2 Glimepiride plus 2/30 Tablets 30 Tablets Pioglitazone Hcl diabetes Metformin Hcl + Improve glycemic control for type 2 Bioglitaplus 15/500 Tablets 20 Tablets Pioglitazone Hcl diabetes Metformin Hcl + Improve glycemic control for type 2 Bioglitaplus 15/850 Tablets 20 Tablets Pioglitazone Hcl diabetes A10BX - Other anti diabetics Control the elevation of blood sugar Megy One 10 mg Tablets Mitiglinide 20 Tablets after eating B- Blood and blood forming organs B01A - Anti-thrombotic agents Andorivaban 10 mg F.C Tablets Rivaroxaban 20 Tablets Anticoagulants Andorivaban 15 mg F.C Tablets Rivaroxaban 20 Tablets Anticoagulants Andorivaban 20
    [Show full text]
  • Dental Management of Patients with Inherited Bleeding Disorders: a Multidisciplinary Approach
    Dental management of patients with inherited bleeding disorders: a multidisciplinary approach Hassan Abed, BDS, MSc ¢ Abdalrahman Ainousa, BDS, MSc Bleeding disorders can be inherited or acquired and leeding disorders can result from inherited genetic demonstrate different levels of severity. Dentists may be defects or be acquired due to use of anticoagulant med- called on to treat patients who have bleeding disor- ications or medical conditions such as liver dysfunc- ders such as hemophilia A and von Willebrand disease B 1-3 tion, chronic kidney disease, and autoimmune disease. During (vWD). Dental extraction in any patient with clotting blood vessel injury, hemostasis relies on interactions between factor defects can result in a delayed bleeding episode. the vascular vessel wall and activated platelets as well as clot- 4 Local hemostatic measures provide effective results in ting factors. Any marked defect at one of these stages results a majority of cases but are insufficient in patients with in bleeding disorders. Vascular wall defects, platelet defects, severe hemophilia A and vWD. Therefore, consultation or deficiency of clotting factors can affect the severity level of 5 with the patient’s hematologist is required to ensure bleeding episodes. Thus, patients may have mild, moderate, or preoperative prophylactic coverage. Dental care provid- severe episodes of bleeding. ers have to be aware of any signs of bleeding disorders and refer patients for further medical investigations. This Sources of inherited bleeding disorders article aims to provide dental care providers with the Vascular wall defects knowledge to manage patients with inherited bleeding A patient’s bleeding disorder may be unrecognized, and bleeding disorders, especially hemophilia A and vWD.
    [Show full text]
  • PACKAGE LEAFLET: INFORMATION for the USER Lercanidipine
    PACKAGE LEAFLET: INFORMATION FOR THE USER Lercanidipine Hydrochloride 10 mg Film-coated Tablets Lercanidipine Hydrochloride 20 mg Film-coated Tablets lercanidipine hydrochloride Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any of the side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What Lercanidipine Hydrochloride Film-coated Tablets is and what it is used for 2. What you need to know before you take Lercanidipine Hydrochloride Film-coated Tablets 3. How to take Lercanidipine Hydrochloride Film-coated Tablets 4. Possible side effects 5. How to store Lercanidipine Hydrochloride Film-coated Tablets 6. Contents of the pack and other information 1. WHAT LERCANIDIPINE HYDROCHLORIDE FILM-COATED TABLETS IS AND WHAT IT IS USED FOR Lercanidipine belongs to a group of medicines called calcium channel blockers (dihydropyridine derivatives) that lower blood pressure.. Lercanidipine is used to treat high blood pressure also known as hypertension in adults over the age of 18 years (it is not recommended for children under 18 years old). 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE LERCANIDIPINE
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone During SARS-Cov-2 Infection
    pharmaceuticals Review COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection Katarzyna Kotfis 1,* , Kacper Lechowicz 1 , Sylwester Drozd˙ zal˙ 2 , Paulina Nied´zwiedzka-Rystwej 3 , Tomasz K. Wojdacz 4, Ewelina Grywalska 5 , Jowita Biernawska 6, Magda Wi´sniewska 7 and Miłosz Parczewski 8 1 Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland; [email protected] 2 Department of Pharmacokinetics and Monitored Therapy, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 3 Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland; [email protected] 4 Independent Clinical Epigenetics Laboratory, Pomeranian Medical University, 71-252 Szczecin, Poland; [email protected] 5 Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] 6 Department of Anesthesiology and Intensive Therapy, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland; [email protected] 7 Clinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 8 Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, 71-455 Szczecin, Poland; [email protected] * Correspondence: katarzyna.kotfi[email protected]; Tel.: +48-91-466-11-44 Abstract: In March 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was declared Citation: Kotfis, K.; Lechowicz, K.; a global pandemic by the World Health Organization (WHO). The clinical course of the disease is Drozd˙ zal,˙ S.; Nied´zwiedzka-Rystwej, unpredictable but may lead to severe acute respiratory infection (SARI) and pneumonia leading to P.; Wojdacz, T.K.; Grywalska, E.; acute respiratory distress syndrome (ARDS).
    [Show full text]
  • Summary of Product Characteristics, Labelling and Package Leaflet
    SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET 1 SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT /.../ 10 mg film-coated tablet /.../ 20 mg film-coated tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains 10 mg lercanidipine hydrochloride, equivalent to 9.4 mg lercanidipine. One film-coated tablet contains 20 mg lercanidipine hydrochloride, equivalent to 18.8 mg lercanidipine. Excipient with known effect: /.../ 10 mg film-coated tablet: Lactose monohydrate 30 mg Excipient with known effect: /.../ 20 mg film-coated tablet: Lactose monohydrate 60 mg For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film--coated tablet /.../ 10 mg film-coated tablet: Yellow, round, biconvex 6.5 mm film-coated tablets, scored on one side, marked 'L' on the other side. /.../ 20 mg film-coated tablet: Pink, round, biconvex 8.5 mm film-coated tablets, scored on one side, marked 'L' on the other side. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications /.../ is indicated for the treatment of mild to moderate essential hypertension. 4.2 Posology and method of administration Posology Route of administration: For oral use. The recommended dosage is 10 mg orally once a day at least 15 minutes before meals; the dose may be increased to 20 mg depending on the individual patient's response. Dose titration should be gradual, because it may take about 2 weeks before the maximal antihypertensive effect is apparent. Some individuals, not adequately controlled on a single antihypertensive agent, may benefit from the addition of lercandipine to therapy with a beta-adrenoreceptor blocking drug, a diuretic (hydrochlorothiazide) or an angiotensin converting enzyme inhibitor.
    [Show full text]
  • The Management of Common Skin Conditions in General Practice
    Management of Common Skin Conditions In General Practice including the “red rash made easy” © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care University of Auckland, Tamaki Campus Reviewed by Hon A/Prof Amanda Oakley - 2019 http://www.dermnetnz.org Management of Common Skin Conditions In General Practice Contents Page Derm Map 3 Classic location: infants & children 4 Classic location: adults 5 Dermatology terminology 6 Common red rashes 7 Other common skin conditions 12 Common viral infections 14 Common bacterial infections 16 Common fungal infections 17 Arthropods 19 Eczema/dermatitis 20 Benign skin lesions 23 Skin cancers 26 Emergency dermatology 28 Clinical diagnosis of melanoma 31 Principles of diagnosis and treatment 32 Principles of treatment of eczema 33 Treatment sequence for psoriasis 34 Topical corticosteroids 35 Combination topical steroid + antimicrobial 36 Safety with topical corticosteroids 36 Emollients 37 Antipruritics 38 For further information, refer to: http://www.dermnetnz.org And http://www.derm-master.com 2 © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care, University of Auckland, Tamaki Campus. Management of Common Skin Conditions In General Practice DERM MAP Start Is the patient sick ? Yes Rash could be an infection or a drug eruption? No Insect Bites – Crop of grouped papules with a central blister or scab. Is the patient in pain or the rash Yes Infection: cellulitis / erysipelas, impetigo, boil is swelling, oozing or crusting? / folliculitis, herpes simplex / zoster. Urticaria – Smooth skin surface with weals that evolve in minutes to hours. No Is the rash in a classic location? Yes See our classic location chart .
    [Show full text]
  • Dorset Medicines Advisory Group
    DORSET CARDIOLOGY WORKING GROUP GUIDELINE FOR CALCIUM CHANNEL BLOCKERS IN HYPERTENSION SUMMARY The pan-Dorset cardiology working group continues to recommend the use of amlodipine (a third generation dihydropyridine calcium-channel blocker) as first choice calcium channel blocker on the pan-Dorset formulary for hypertension. Lercanidipine is second choice, lacidipine third choice and felodipine is fourth choice. This is due to preferable side effect profiles in terms of ankle oedema and relative costs of the preparations. Note: where angina is the primary indication or is a co-morbidity prescribers must check against the specific product characteristics (SPC) for an individual drug to confirm this is a licensed indication. N.B. Lacidipine and lercandipine are only licensed for use in hypertension. Chapter 02.06.02 CCBs section of the Formulary has undergone an evidence-based review. A comprehensive literature search was carried out on NHS Evidence, Medline, EMBASE, Cochrane Database, and UK Duets. This was for recent reviews or meta-analyses on calcium channel blockers from 2009 onwards (comparative efficacy and side effects) and randomised controlled trials (RCTs). REVIEW BACKGROUND Very little good quality evidence exists. No reviews, meta-analyses or RCTs were found covering all calcium channel blockers currently on the formulary. Another limitation was difficulty obtaining full text original papers for some of the references therefore having to use those from more obscure journals instead. Some discrepancies exist between classification of generations of dihydropyridine CCBs, depending upon the year of publication of the reference/authors’ interpretation. Dihydropyridine (DHP) CCBs tend to be more potent vasodilators than non-dihydropyridine (non-DHP) CCBs (diltiazem, verapamil), but the latter have greater inotropic effects.
    [Show full text]
  • Oregon Medicaid PA Criteria for Fee-For-Service Prescriptions
    Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria HEALTH SYSTEMS DIVISION Prior authorization (PA) criteria for fee-for-service prescriptions for Oregon Health Plan clients March 29, 2017 Contents Contents ................................................................................................................................................................ 2 Introduction........................................................................................................................................................... 6 About this guide ......................................................................................................................................... 6 How to use this guide ................................................................................................................................. 6 Administrative rules and supplemental information .................................................................................. 6 Update information .............................................................................................................................................. 7 Effective March 29, 2017 .......................................................................................................................... 7 Substantive updates and new criteria ............................................................................................. 7 Clerical changes ............................................................................................................................
    [Show full text]
  • Efficacy of 2% Lidocaine and 4% Articaine in Mandibular Molars with Different Pulp Diagnoses in the Mandibular Technique1
    Efficacy of 2% lidocaine and 4% articaine in mandibular molars with different pulp diagnoses in the mandibular technique1 Eficacia de la lidocaína al 2% y la articaína al 4% en molares mandibulares con diferentes diagnósticos pulpares en la técnica mandibular1 Adel Martínez Martínez2, Evelyn Freyle Granados3, Natalia Senior Carmona3 1 Paper submitted in partial fulfillment of the requirements for the degree of Endodontist 2 Assistant Professor, GITOUC Group, School of Dentistry, Universidad de Cartagena 3 DDS, Specialist in Endodontics, Postgraduate program in Endodontics, School of Dentistry, Universidad de Cartagena ABSTRACT Introduction: the inferior alveolar dental nerve block is the method most commonly used by endodontists to achieve local anesthesia during treatments. This study compared the efficacy of two anesthetic solutions: 2% lidocaine with 1:80,000 epinephrine and 4% articaine with 1:100,000 epinephrine in patients with different ARTICLES ORIGINAL pulp diagnoses requiring endodontic treatment. Method: an interventional, randomized clinical trial. The sample included 36 patients who were treated at the postgraduate endodontics service at the Universidad de Cartagena in the year 2016. Descriptive statistics and the Chi2 test were used for data analysis, using a limit of 0.05. Results: articaine showed a greater anesthetic effect in vestibular mucosa (88.9%) and tip of tongue (55.6%), compared with lidocaine. The rates of anesthetic success in the lidocaine and articaine groups were 5.6% and 22.2% respectively, but this difference was not statistically significant (p = 0.633). In teeth with normal pulp, the efficacy was 27.3%, and this value considerably decreased in teeth with asymptomatic and symptomatic irreversible pulpitis, with percentages of 5.8% and 12.5% respectively, although this difference was not statistically significant (p = 0.276).
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]